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Introduction {#sec1}
============

Intracellular Ca^2+^ signaling in pancreatic islets is important for their endocrine function, particularly insulin secretion. Ca^2+^ signaling evoked by glucose stimulation shows the unique feature of oscillatory increases regulated by an interplay between Ca^2+^ influx through voltage-gated L-type Ca^2+^ channels and Ca^2+^ mobilization from intracellular stores ([@bib10], [@bib35]). Accumulating evidences suggest that both the amplitude and the frequency of cytosolic Ca^2+^ (\[Ca^2+^\]~i~) oscillations in the islets are important and that these are altered in subjects with type 2 diabetes mellitus (T2DM). In a diabetic mouse model, the amplitude of \[Ca^2+^\]~i~ changes decreased and the response to glucose was delayed, concurrent with a disappearance of \[Ca^2+^\]~i~ oscillations ([@bib7], [@bib17]). Similar findings have been reported for islets from diabetic patients ([@bib14], [@bib15], [@bib28], [@bib30], [@bib41]). In this context, it is noteworthy that restoration of Ca^2+^ signaling has been shown to result in improved glucose tolerance ([@bib1], [@bib27]). Although a number of genes associated with β cell dysfunction in T2DM have been identified ([@bib11], [@bib16], [@bib18], [@bib21], [@bib44]), the molecular mechanisms underlying alterations in Ca^2+^ dynamics in T2DM have not yet been well defined.

Voltage-gated Ca^2+^ channels (Ca~v~) play a critical role in intracellular Ca^2+^ signaling and insulin exocytosis ([@bib33], [@bib34], [@bib42]). They are composed of four subunits: a pore-forming α1 subunit; α2/δ; β; and γ subunits. The β subunit is anchored to the intracellular side of the membrane and modifies Ca^2+^ channel currents through binding to the pore-forming α1 subunit ([@bib5], [@bib39]). Among the four types of β subunits, the β3 subunit (Ca~v~β~3~) is mainly expressed in pancreatic islets in addition to the β2 subunit (Ca~v~β~2~). In a previous study, we reported that islets from Ca~v~β~3~- deficient (Ca~v~β~3~^−/−^) mice showed an increased frequency of \[Ca^2+^\]~i~ oscillations and better insulin secretion, and Ca~v~β~3~^−/−^ mice were more glucose tolerant than wild-type mice ([@bib2]). However, the role of Ca~v~β~3~ in diabetes remains unclear.

Here, we report that Ca~v~β~3~ plays a major role in alterations of Ca^2+^ dynamics and subsequent insulin secretion in the diabetic islets. We observed that the protein level of Ca~v~β~3~ in islets from diabetic mice was elevated and that \[Ca^2+^\]~i~ dynamics in response to a high glucose concentration were altered. Deficiency of Ca~v~β~3~ prevented the alteration of Ca^2+^ signaling during diabetes progression. Decreased expression of Ca~v~β~3~ in islets from diabetic mice showed improvement of \[Ca^2+^\]~i~ dynamics and insulin secretion compared to islets from control mice, resulting in ameliorated glucose tolerance in the mice. Therefore, targeting of Ca~v~β~3~ may be a therapeutic strategy in T2DM.

Results {#sec2}
=======

Pancreatic Islets from ob/ob Mice Overexpress Ca~v~β~3~ and Have Altered \[Ca^2+^\]~i~ Dynamics and Insulin Secretion {#sec2.1}
---------------------------------------------------------------------------------------------------------------------

We investigated the relationship between diabetes and Ca~v~β~3~ using B6.Cg-Lep^ob^/J (ob/ob) mice, a diabetic mouse model. First, we compared Ca~v~β~3~ protein levels in islets from 8- to 12-week-old ob/ob mice with those in islets from lean mice. The protein level of Ca~v~β~3~ in islets from ob/ob mice was significantly higher than that in islets from control (lean) mice ([Figure 1](#fig1){ref-type="fig"}A). Considering the phenotype of Ca~v~β~3~^−/−^ mice with the shorter oscillation periods in Ca^2+^ signaling and improved glucose-induced insulin secretion (GIIS), we anticipated opposite changes in ob/ob mice. We measured \[Ca^2+^\]~i~ dynamics in islets from ob/ob and lean mice upon high-glucose (11 mM) stimulation. Representative Ca^2+^ traces are shown in [Figures 1](#fig1){ref-type="fig"}B and 1C. The first-peak amplitudes in glucose-induced Ca^2+^ traces were lower in islets from ob/ob mice than in those from lean mice ([Figure 1](#fig1){ref-type="fig"}D). For quantitative analysis of the oscillatory patterns, we analyzed the period and amplitude of oscillations based on the power spectral density. Islets from ob/ob mice showed oscillations of longer period and smaller amplitude than islets from lean mice ([Figures 1](#fig1){ref-type="fig"}E and 1F). To check Ca^2+^ increase dependent on Ca~v~, we depolarized dissociated islet cells by 25 mM KCl. The \[Ca^2+^\]~i~ peak in islet cells from ob/ob mice was lower than that in islet cells from lean mice ([Figures 1](#fig1){ref-type="fig"}G and 1H). GIIS was lower in islets from ob/ob mice than in those from lean mice ([Figure 1](#fig1){ref-type="fig"}I). Consistent with these results, glucose intolerance was significantly higher in ob/ob mice than in control lean mice ([Figure 1](#fig1){ref-type="fig"}J). Hence, we observed overexpression of Ca~v~β~3~ and alterations in \[Ca^2+^\]~i~ dynamics, including smaller amplitudes of the first peak of glucose-induced Ca^2+^ increases and longer oscillation periods and smaller oscillation amplitudes, in islets from ob/ob mice. These changes result in impaired GIIS and overall impaired *in vivo* glucose tolerance.Figure 1Ca~v~β~3~ Expression and \[Ca^2+^\]~i~ Dynamics Were Altered in Islets from ob/ob Mice(A) Left panel shows protein levels of Ca~v~β~3~ in islets from control lean mice and ob/ob mice. Right panel shows relative quantification of Ca~v~β~3~ protein expression in left panel (n = 5; 40 islets in each case).(B and C) Effects of 11 mM glucose on \[Ca^2+^\]~i~ in islets from control (B) and ob/ob mice (C). Representative traces out of 39 for lean and ob/ob islets are shown.(D) First peak ratios of glucose-induced \[Ca^2+^\]~i~ changes in islets from control lean and ob/ob mice.(E) Oscillation periods of glucose-induced \[Ca^2+^\]~i~ changes in islets from control lean and ob/ob mice.(F) Oscillation amplitudes of glucose-induced \[Ca^2+^\]~i~ changes in islets from control lean mice and ob/ob mice.(G) Effects of 25 mM KCl on \[Ca^2+^\]~i~ in dissociated islet cells from control lean (black) and ob/ob (red) mice. Representative traces in dissociated islet cells from control lean and ob/ob mice are shown.(H) Peak ratios of \[Ca^2+^\]~i~ changes induced by 25 mM KCl in dissociated islet cells from lean (black) and ob/ob (red) mice (n = 10; each experiment included 50 single cells).(I) Glucose-induced insulin release in islets from control lean and ob/ob mice. The islets were treated with 3 mM or 11 mM glucose for 30 min (n = 5; 10 islets in each case).(J) Left panel shows intraperitoneal glucose tolerance test in control lean and ob/ob mice (n = 5 each). Right panel shows comparison of areas under the curves from left panel.Data are presented as the mean ± SEM; ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001.

Pancreatic Islets from HFD-Fed Mice Overexpress Ca~v~β~3~ and Show Altered \[Ca^2+^\]~i~ Dynamics and Insulin Secretion {#sec2.2}
-----------------------------------------------------------------------------------------------------------------------

Next, we investigated the relationship between Ca~v~β~3~ and diabetes using high-fat diet (HFD)-fed mice, another model of T2DM. As in ob/ob mice, the Ca~v~β~3~ protein level was higher in islets from mice fed a HFD for 8 weeks than in islets from normal chow diet (NCD)-fed mice ([Figure 2](#fig2){ref-type="fig"}A). Representative Ca^2+^ traces upon 11 mM glucose stimulation are shown in [Figures 2](#fig2){ref-type="fig"}B and 2C. First-peak amplitudes in glucose-induced Ca^2+^ traces were lower in islets from HFD-fed mice compared to those of NCD-fed mice ([Figure 2](#fig2){ref-type="fig"}D). Based on the power spectral density, we found that islets from HFD-fed mice produced oscillations of longer period ([Figure 2](#fig2){ref-type="fig"}E) and smaller amplitude ([Figure 2](#fig2){ref-type="fig"}F). However, 25 mM KCl did not induce significant differences in Ca^2+^ influx between islets from HFD-fed mice and those from NCD-fed mice ([Figures 2](#fig2){ref-type="fig"}G and 2H). Nevertheless, GIIS was lower in islets from HFD-fed mice than in islets from NCD-fed mice ([Figure 2](#fig2){ref-type="fig"}I). HFD-fed mice showed stronger glucose intolerance than NCD-fed mice ([Figure 2](#fig2){ref-type="fig"}J). Collectively, these results revealed overexpression of Ca~v~β~3~, alterations in Ca^2+^ dynamics, and insulin secretion in islets from HFD-fed mice, similar to the observations made in ob/ob mice. Based on these findings, which were opposite to the results obtained in Ca~v~β~3~^−/−^ mice, we suspected that overexpression of Ca~v~β~3~ might be a causative factor underlying altered \[Ca^2+^\]~i~ dynamics and insulin secretion in diabetic islets.Figure 2Ca~v~β~3~ Expression and \[Ca^2+^\]~i~ Dynamics Were Altered in Islets of HFD Mice(A) Left panel shows protein levels of Ca~v~β~3~ in islets from NCD and HFD B6 mice. Right panel shows relative quantification of Ca~v~β~3~ protein expression in left panel (n = 5; 40 islets in each case).(B and C) Effects of 11 mM glucose on \[Ca^2+^\]~i~ in islets from NCD (B) and HFD (C) B6 mice. Representative traces out of 30 for NCD and HFD islets are shown.(D) First peak ratios of glucose-induced \[Ca^2+^\]~i~ changes in islets from NCD and HFD B6 mice.(E) Oscillation periods of glucose-induced \[Ca^2+^\]~i~ changes in islets from NCD and HFD B6 mice.(F) Oscillation amplitudes of glucose-induced \[Ca^2+^\]~i~ changes in islets from NCD and HFD B6 mice.(G) Effects of 25 mM KCl on \[Ca^2+^\]~i~ in dissociated islet cells from NCD (black) and HFD (red) B6 mice. Representative traces on dissociated islet cells from NCD and HFD B6 mice are shown.(H) Peak ratios of \[Ca^2+^\]~i~ changes induced by 25 mM KCl in dissociated islet cells from NCD (black) and HFD (red) B6 mice (n = 10; each experiment involved 50 single cells).(I) Glucose-induced insulin release in islets from NCD and HFD B6 mice. Islets were treated with 3 mM or 11 mM glucose for 30 min (n = 5; 10 islets in each case).(J) Left panel shows intraperitoneal glucose tolerance test in NCD and HFD B6 mice (n = 5 in each case). Right panel shows comparison of areas under the curves from left panel.Data are presented as the mean ± SEM; ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001.

Ca~v~β~3~ Overexpression in Pancreatic Islets Alters \[Ca^2+^\]~i~ Dynamics and Insulin Secretion {#sec2.3}
-------------------------------------------------------------------------------------------------

To investigate whether the altered \[Ca^2+^\]~i~ dynamics and impaired insulin secretion in diabetic islets are directly resulting from Ca~v~β~3~ overexpression, we measured these parameters in islets from C57BL/6 mice overexpressing Ca~v~β~3~ ([Figure 3](#fig3){ref-type="fig"}A) and compared with islets from control mice. First-peak amplitudes in the glucose-induced Ca^2+^ traces were lower in islets overexpressing Ca~v~β~3~ than in control islets expressing GFP ([Figures 3](#fig3){ref-type="fig"}B--3D). Oscillation periods were longer and amplitudes smaller in islets from Ca~v~β~3~-overexpressing mice compared to those from control mice ([Figures 3](#fig3){ref-type="fig"}E and 3F). Upon depolarization of dissociated islet cells with 25 mM KCl, \[Ca^2+^\]~i~ peak amplitudes in islet cells overexpressing Ca~v~β~3~ were lower than those in control islet cells ([Figures 3](#fig3){ref-type="fig"}G and 3H). In our previous study, we suggested that an increase in inositol triphosphate (IP~3~)-mediated Ca^2+^ release from endoplasmic reticulum (ER) might contribute to changes in \[Ca^2+^\]~i~ oscillation frequency and insulin secretion in Ca~v~β~3~ KO islets ([@bib2]). To check whether this mechanism is involved in islets overexpressing Ca~v~β~3~, we stimulated islet cells overexpressing Ca~v~β~3~ and control islet cells with carbamylcholine (Cch), triggering the cholinergic-mediated IP~3~ signaling pathway. The resulting peak in \[Ca^2+^\]~i~ increase in islet cells overexpressing Ca~v~β~3~ was lower than that in controls ([Figure 3](#fig3){ref-type="fig"}I). GIIS was also lower after stimulation with 11 mM glucose in islet cells overexpressing Ca~v~β~3~ ([Figure 3](#fig3){ref-type="fig"}J). The results obtained in islets or islet cells overexpressing Ca~v~β~3~ were consistent with the findings in ob/ob and HFD-fed mice. To shed some light on how Ca~v~β~3~ levels can be elevated in diabetic islets, we investigated potential effects of several factors, such as glucose, insulin, and inflammatory cytokines, known to be associated with diabetes progression. Tumor necrosis factor alpha (TNF-α) or interleukin-1β (IL-1β) significantly increased protein levels of Ca~v~β~3~ in isolated islets ([Figure S1](#mmc1){ref-type="supplementary-material"}). This suggests that proinflammatory cytokines may induce overexpression of Ca~v~β~3~ in islets and thereby cause islet cell dysfunction.Figure 3Overexpression of Ca~v~β~3~ Altered \[Ca^2+^\]~i~ Dynamics in Pancreatic Islets(A) Left panel shows protein levels of Ca~v~β~3~ in control and Ca~v~β~3~-overexpressing adenovirus-treated islet. Right panel shows relative quantification of Ca~v~β~3~ protein levels in left panel (n = 5; 40 islets in each case).(B and C) Effects of 11 mM glucose on \[Ca^2+^\]~i~ in control (B) and Ca~v~β~3~-overexpressing (C) islets. Representative traces out of 30 for both control and Ca~v~β~3~-overexpressing islets are shown.(D) First peak ratios of glucose-induced \[Ca^2+^\]~i~ changes in control and Ca~v~β~3~-overexpressing islets.(E) Oscillation periods of glucose-induced \[Ca^2+^\]~i~ changes in control and Ca~v~β~3~-overexpressing islets.(F) Oscillation amplitudes of glucose-induced \[Ca^2+^\]~i~ changes in control and Ca~v~β~3~-overexpressing islets.(G) Effects of 25 mM KCl on \[Ca^2+^\]~i~ in control islet cells (black) and Ca~v~β~3~-overexpressing islet cells (red). Representative traces of each group are shown.(H) Peak ratios of \[Ca^2+^\]~i~ changes induced by 25 mM KCl in control islet cells (black) and Ca~v~β~3~-overexpressing islet cells (red; n = 10; each experiment involved 50 single cells).(I) Peak ratios of \[Ca^2+^\]~i~ changes induced by 200 μM Cch in control islet cells and Ca~v~β~3~-overexpressing islet cells (n = 5; each experiment involved 30 single cells).(J) Glucose-induced insulin release in control and Ca~v~β~3~-overexpressing islets. Islets treated with 3 mM or 11 mM glucose for 30 min (11 mM glucose/3 mM glucose) are shown (n = 5; 10 islets in each case).The data are presented as the mean ± SEM; ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001. See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

Pancreatic Islets from Ca~v~β~3~^−/−^ Mice Exposed to HFD Have Ameliorated \[Ca^2+^\]~i~ Dynamics and Insulin Secretion {#sec2.4}
-----------------------------------------------------------------------------------------------------------------------

We examined whether Ca~v~β~3~ had a direct role in the islet dysfunction observed in the HFD model. Ca~v~β~3~^−/−^ mice and their littermate controls were fed HFD for eight weeks, and no significant difference in body weight changes was observed between the two groups ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Next, we investigated \[Ca^2+^\]~i~ dynamics in the islets from control and Ca~v~β~3~^−/−^ mice ([Figures 4](#fig4){ref-type="fig"}B and 4C). First-peak amplitudes in the glucose-induced Ca^2+^ traces were higher in islets from HFD-fed Ca~v~β~3~^−/−^ mice than in those from control animals fed the HFD ([Figure 4](#fig4){ref-type="fig"}D). Ca~v~β~3~^−/−^ islets showed shorter oscillation periods and larger amplitudes ([Figures 4](#fig4){ref-type="fig"}E and 4F). There was no significant difference in the \[Ca^2+^\]~i~ peak after stimulation with 25 mM KCl between Ca~v~β~3~^−/−^ and control islet cells ([Figures 4](#fig4){ref-type="fig"}G and 4H). This was in agreement with similar KCl-stimulated responses in islets from control mice fed NCD and in islets from control mice fed HFD ([Figure 2](#fig2){ref-type="fig"}H). We also compared effects of Cch in islets from Ca~v~β~3~^−/−^ mice and their littermate controls fed HFD. Ca~v~β~3~^−/−^ islets showed increased peak of \[Ca^2+^\]~i~ compared to control islets ([Figure 4](#fig4){ref-type="fig"}I), which is consistent with the Cch effect in islets overexpressing Ca~v~β~3~ ([Figure 3](#fig3){ref-type="fig"}I). The compromised GIIS in islets from HFD-fed mice was also improved in islets from HFD-fed Ca~v~β~3~^−/−^ mice ([Figure 4](#fig4){ref-type="fig"}J). Consistent with the results on \[Ca^2+^\]~i~ dynamics and insulin secretion, glucose tolerance in Ca~v~β~3~^−/−^ mice on HFD was better than that in control mice ([Figure 4](#fig4){ref-type="fig"}K), and insulin tolerance was not significantly different ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Plasma insulin level at 30 min after glucose injection was higher in HFD-fed Ca~v~β~3~^−/−^ mice ([Figure 4](#fig4){ref-type="fig"}L). Although the fasting insulin level was not significantly different in HFD-fed Ca~v~β~3~^−/−^ mice compared to lean mice ([Figure S2](#mmc1){ref-type="supplementary-material"}C), non-fasting insulin levels were higher in HFD-fed Ca~v~β~3~^−/−^ mice ([Figure S2](#mmc1){ref-type="supplementary-material"}D). Therefore it is likely that an increase in *in vivo* GIIS explains the better glucose tolerance in HFD-fed Ca~v~β~3~^−/−^ mice. Based on these observations, we suggest that overexpression of Ca~v~β~3~ is an important factor causing islet dysfunction in diabetes development, and regulation of the Ca~v~β~3~ level could lead to an improvement of islet function and glucose homeostasis.Figure 4Ca~v~β~3~^−/−^ Mice Fed a HFD Show a Less Severe Diabetic Phenotype(A) Protein levels of Ca~v~β~3~ in islets from control mice fed a HFD and Ca~v~β~3~^−/−^ mice fed a HFD (n = 5; 40 islets in each case).(B and C) Effects of 11 mM glucose on \[Ca^2+^\]~i~ in islets from control mice fed a HFD (B) and Ca~v~β~3~^−/−^ mice fed a HFD (C). Representative traces out of 30 are shown.(D) First peak ratios of glucose-induced \[Ca^2+^\]~i~ changes in islets from control mice and Ca~v~β~3~^−/−^ mice fed a HFD.(E) Oscillation periods of glucose-induced \[Ca^2+^\]~i~ changes in islets from control mice and Ca~v~β~3~^−/−^ mice fed a HFD.(F) Oscillation amplitudes of glucose-induced \[Ca^2+^\]~i~ changes in islets from control mice and Ca~v~β~3~^−/−^ mice fed a HFD.(G) Effects of 25 mM KCl on \[Ca^2+^\]~i~ in dissociated islet cells from control mice (black) and Ca~v~β~3~^−/−^ mice (red) fed a HFD. Representative traces on dissociated islet cells are shown.(H) Peak ratios of \[Ca^2+^\]~i~ changes induced by 25 mM KCl in dissociated islet cells from control mice (black) and Ca~v~β~3~^−/−^ mice (red) fed a HFD (n = 5; each experiment involved 50 single cells).(I) Peak ratios of \[Ca^2+^\]~i~ changes induced by 200 μM Cch in dissociated islet cells from Ca~v~β~3~^−/−^ mice fed a HFD and control mice fed a HFD (n = 5; each experiment involved 30 single cells).(J) Glucose-induced insulin release from islets of control and Ca~v~β~3~^−/−^ mice fed a HFD. Islets were treated with 3 mM or 11 mM glucose for 30 min (n = 3; 10 islets in each case).(K) Left panel shows intraperitoneal glucose tolerance test of control and Ca~v~β~3~^−/−^ mice fed a HFD (n = 4 in each case). Right panel shows comparison of areas under the curves from left panel.(L) Plasma insulin levels 30 min after glucose injection from fasted control mice (black) and Ca~v~β~3~^−/−^ mice (red) fed a HFD (n = 5 in each case).Data are presented as the mean ± SEM; ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Treatment with Antisense Oligonucleotide Targeting Ca~v~β~3~ Improves \[Ca^2+^\]~i~ Dynamics and Insulin Secretion in ob/ob Islets {#sec2.5}
----------------------------------------------------------------------------------------------------------------------------------

The next question was whether decreasing expression of Ca~v~β~3~ could improve Ca^2+^ dynamics and insulin secretion in the diabetes onset condition. We tested this idea in ob/ob islets from 8- to 12-week-old mice by treatment with antisense oligonucleotide targeting Ca~v~β~3~ (Ca~v~β~3~ ASO). Treatment with Ca~v~β~3~ ASO effectively reduced Ca~v~β~3~ expression in the ob/ob islets ([Figure 5](#fig5){ref-type="fig"}A). We measured glucose-induced Ca^2+^ dynamics in ob/ob islets treated with Ca~v~β~3~ ASO or scramble ASO ([Figures 5](#fig5){ref-type="fig"}B and 5C). First-peak amplitudes in glucose-induced Ca^2+^ traces were significantly higher in ob/ob islets after Ca~v~β~3~ ASO treatment ([Figure 5](#fig5){ref-type="fig"}D). Islets treated with Ca~v~β~3~ ASO showed shorter oscillation periods ([Figure 5](#fig5){ref-type="fig"}E) and larger amplitudes ([Figure 5](#fig5){ref-type="fig"}F), as indicated by power spectral analysis. Upon stimulation with 25 mM KCl, dissociated islet cells treated with Ca~v~β~3~ ASO showed higher Ca^2+^ peak ratios than islet cells treated with scramble ASO ([Figures 5](#fig5){ref-type="fig"}G and 5H). Moreover, treatment with Ca~v~β~3~ ASO, compared to treatment with scramble ASO, increased Cch-induced Ca^2+^ release in islet cells from ob/ob mice ([Figure 5](#fig5){ref-type="fig"}I). Consistent with the Ca^2+^-influx results, islets treated with Ca~v~β~3~ ASO showed improved GIIS ([Figure 5](#fig5){ref-type="fig"}J).Figure 5Treatment with Antisense Oligonucleotide Targeting Ca~v~β~3~ Improves \[Ca^2+^\]~i~ Dynamics and Insulin Secretion in ob/ob Islets(A) Left panel shows protein levels of Ca~v~β~3~ in ob/ob islets treated with scramble ASO and Ca~v~β~3~ ASO. Right panel shows relative quantification of Ca~v~β~3~ protein levels in left (n = 5; 40 islets in each case).(B and C) Effects of 11 mM glucose on \[Ca^2+^\]~i~ in ob/ob islets treated with scramble ASO (B) and Ca~v~β~3~ ASO (C). Representative traces out of 30 are shown.(D) First peak ratios of glucose-induced \[Ca^2+^\]~i~ changes in ob/ob islets treated with scramble ASO and Ca~v~β~3~ ASO.(E) Oscillation periods of glucose-induced \[Ca^2+^\]~i~ changes in ob/ob islets treated with scramble ASO and Ca~v~β~3~ ASO.(F) Oscillation amplitudes of glucose-induced \[Ca^2+^\]~i~ changes in ob/ob islets treated with scramble ASO and Ca~v~β~3~ ASO.(G) Effects of 25 mM KCl on \[Ca^2+^\]~i~ in dissociated islet cells from scramble ASO (black) and Ca~v~β~3~-ASO-treated (red) ob/ob mice. Representative traces on dissociated islet cells are shown.(H) Peak ratios of \[Ca^2+^\]~i~ changes induced by 25 mM KCl in dissociated islet cells from scramble ASO (black) and Ca~v~β~3~-ASO-treated (red) ob/ob mice (n = 5; each experiment involved 50 single cells).(I) Peak ratios of \[Ca^2+^\]~i~ changes induced by 200 μM Cch in ob/ob-dissociated islet cells treated with scramble ASO and Ca~v~β~3~ ASO (n = 5; each experiment involved 30 single cells).(J) Glucose-induced insulin release in ob/ob islets treated with scramble ASO and Ca~v~β~3~ ASO. The islets were treated with 3 mM or 11 mM glucose for 30 min (n = 5; 10 islets in each case).Data are presented as the means ± SEM; ^∗^p \< 0.05, ^∗∗∗^p \< 0.001. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Transplantation of Ca~v~β~3~^−/−^ Islets Improves Glycemic Control in HFD-Fed Mice {#sec2.6}
----------------------------------------------------------------------------------

To assess the effect of targeting Ca~v~β~3~ in pancreatic islets after diabetes onset *in vivo*, we transplanted islets from Ca~v~β~3~^−/−^ mice and control littermates into the anterior chamber of the eye in diabetic mice. C57BL/6J mice were put on a HFD during the whole period of the experiment. After eight weeks of HFD feeding, the animals were treated with streptozotocin to avoid an effect of endogenous pancreatic islets. Thereafter, islet transplantations were performed ([Figures 6](#fig6){ref-type="fig"}A and 6B). Three weeks later, we imaged islet vascularization *in vivo* ([Figure 6](#fig6){ref-type="fig"}C). Vessel diameters inside the islets did not significantly differ between Ca~v~β~3~^−/−^ islet-transplanted and control islet-transplanted mice ([Figure S3](#mmc1){ref-type="supplementary-material"}A). The blood glucose level was decreased in both Ca~v~β~3~^−/−^ and control islet-transplanted mice ([Figure S3](#mmc1){ref-type="supplementary-material"}B). After 4 weeks, when transplanted islets are fully vascularized and innervated, we performed glucose tolerance tests. From five weeks after transplantation, glucose tolerance in mice transplanted with Ca~v~β~3~^−/−^ islets improved as compared with mice transplanted with control islets. We presented the results obtained six weeks after transplantation, when glucose tolerance was more significantly improved. The area under the curve was significantly lower in Ca~v~β~3~^−/−^ islet-transplanted compared to control islet-transplanted mice ([Figure 6](#fig6){ref-type="fig"}D). However, insulin tolerance was not significantly different ([Figure 6](#fig6){ref-type="fig"}E). In short, glucose clearance, but not insulin sensitivity, was improved in Ca~v~β~3~^−/−^ islet-transplanted mice. These results suggest that suppression of Ca~v~β~3~ after the time of onset of diabetes can significantly improve the diabetes phenotype in mice.Figure 6Metabolic Transplantation of Ca~v~β~3~^−/−^ Islet Improves Glucose Control under Diabetic Conditions(A) Schematic diagram of experimental protocol.(B) Representative photograph of islets engrafted on the iris.(C) Representative islet vessel images; maximum projections of image stacks of an islet graft in the anterior chamber of the eye three weeks after transplantation. Islet is green, and blood vessels are red (Texas Red staining). The scale bar represents 100 μm.(D) Left panel shows intraperitoneal glucose tolerance tests in HFD-fed mice transplanted with islets from control and Ca~v~β~3~^−/−^ mice (n = 8 in each case). Right panel shows comparison of areas under the curves from left panel.(E) Intraperitoneal insulin tolerance test in HFD-fed mice transplanted with islets from control and Ca~v~β~3~^−/−^ mice (n = 8 in each case).Data are presented as the mean ± SEM; ^∗^p \< 0.05 and ^∗∗^p \< 0.01. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Overexpression of Ca~v~β~3~ Disrupts GIIS in Human Islets {#sec2.7}
---------------------------------------------------------

To investigate whether Ca~v~β~3~ functions in human islets, we overexpressed Ca~v~β~3~ in islets from individual donors using adenovirus ([Figure 7](#fig7){ref-type="fig"}A) and measured GIIS. Overexpression of Ca~v~β~3~ decreased insulin secretion specifically in the presence of a high-glucose concentration, whereas it didn't affect basal insulin secretion ([Figures 7](#fig7){ref-type="fig"}B and 7C). From these results, we suggest that overexpression of Ca~v~β~3~ might have a similar role in human islets as in rodent islets, namely decreasing GIIS.Figure 7Ad-Ca~v~β~3~-Transduced Human Islets Display Impaired Glucose-Stimulated Insulin Secretion(A) Sample confocal images of control (left panel) and Ca~v~β~3~-overexpressing human islets (right panel).(B) Insulin secretion from control or Ca~v~β~3~-overexpressing islets of individual human donors incubated with 3 mM or 11 mM glucose.(C) Average insulin secretion from control or Ca~v~β~3~-overexpressing islets of human donors incubated with 3 mM or 11 mM glucose.Data are presented as mean ± SEM; ^\#^p \< 0.01 versus 3 mM glucose/Ad-GFP, ^¤^p \< 0.05 versus 11 mM glucose/Ad-GFP, and ^∗∗^p \< 0.01 versus 11--3 mM glucose/Ad-GFP. The scale bars represent 20 μm. Δ Insulin, insulin released from islets incubated with 11 mM glucose minus that from islets incubated with 3 mM glucose.

Discussion {#sec3}
==========

Ca^2+^ signaling in pancreatic β cell is critical for glucose-induced insulin secretion to regulate blood glucose levels. A number of studies have suggested that Ca^2+^ signaling is disturbed in T2DM through changes in Ca~v~ activity or intracellular Ca^2+^ release ([@bib9], [@bib17], [@bib29], [@bib32], [@bib40]). In this study, we showed that Ca~v~β~3~ was overexpressed in diabetic mouse islets and that this was important for progression of T2DM. Based on our results obtained with ASO treatment and islet transplantation, we suggest that Ca~v~β~3~ could be a target for treatment of T2DM.

Overexpression of Ca~v~β~3~ in pancreatic islets led to alterations in Ca^2+^ dynamics during diabetes progression. Alterations in Ca^2+^ dynamics in diabetic islets, including decreases in the amplitude of Ca^2+^ influx induced by glucose and elongation of the period of Ca^2+^ oscillations, have been previously reported ([@bib6], [@bib7], [@bib17], [@bib37]). In our experiments using islets from ob/ob and HFD-fed mice, we also consistently observed that these phenotypes concur with overexpression of Ca~v~β~3~ and that overexpression of Ca~v~β~3~ per se induced similar changes in Ca^2+^ dynamics. In a series of experiments where we reduced Ca~v~β~3~ expression in diabetic islets, the changes in Ca^2+^ dynamics were reversed. Together, these results indicate that Ca~v~β~3~ is responsible for the alterations in Ca^2+^ dynamics in diabetic mouse islets.

Future studies will reveal how Ca~v~β~3~ mechanistically decreases Ca^2+^ conductance ([Figure S4](#mmc1){ref-type="supplementary-material"}) and increases the Ca^2+^ oscillation period. Ca~v~β~3~ is mainly known as a subunit that can regulate Ca~v~ activity. Ca~v~β~3~ binds a highly conserved sequence located in the intracellular loop joining the α interaction domain of the α1 subunit, thus tightly regulating pore opening ([@bib5], [@bib39]). In other cell systems, Ca~v~β~3~ generally increased Ca~v~ activity by channel localization or regulation of voltage-dependent activation or inhibition, a phenotype opposite to that observed in our study ([@bib3], [@bib20], [@bib24], [@bib26]). Decrease of Ca^2+^ conductance by overexpression of Ca~v~β~3~ seems to be dependent on the cellular and/or molecular context. One study showed that overexpression of Ca~v~β~3~ decreased the activity of N type and R type Ca~v~ channels, but not that of L-type Ca^2+^ channels ([@bib43]). In pancreatic islets, we have previously shown that removal of Ca~v~β~3~ did not change Ca~v~ activity under normal physiological conditions although it increased Ca^2+^ oscillation frequency. Hence, Ca~v~β~3~ may have a unique mode of action in pancreatic islets that is lacking in other cells and that this feature is particularly important for the progression of diabetes. For the regulation of Ca^2+^ oscillation pattern by Ca~v~β~3~, we previously suggested that IP~3~-mediated Ca^2+^ release from ER might be important ([@bib2]). In the present study, we showed that overexpression of Ca~v~β~3~ decreased Cch-induced Ca^2+^ release and that this effect was restored by decreasing Ca~v~β~3~ levels ([Figures 3](#fig3){ref-type="fig"}I, [4](#fig4){ref-type="fig"}I, and [5](#fig5){ref-type="fig"}I). These results led us to hypothesize that overexpression of Ca~v~β~3~ in diabetes negatively impacts ER Ca^2+^ handling and eventually leads to ER stress. ER stress has been associated with the loss of insulin secretion in T2DM ([@bib31]) and is thought to be a major contributor to islet dysfunction ([@bib22]). However, we could not observe significant changes in ER stress markers between ob/ob islets treated with Ca~v~β~3~-ASO or scrambled ASO under conditions where we observed improvement of Ca^2+^ dynamics and insulin secretion ([Figure S5](#mmc1){ref-type="supplementary-material"}). Although we cannot exclude that Ca~v~β~3~ is involved in ER stress at the later time points of diabetes progression, ER stress may not be the primary mechanism whereby Ca~v~β~3~ exerts its negative effects on β cell function.

We propose Ca~v~β~3~ as a potential target for diabetes treatment. We showed that decreasing the level of Ca~v~β~3~ in ob/ob islets recovered their GIIS and that transplantation of Ca~v~β~3~^−/−^ islets into HFD-induced diabetic mice could recover glucose intolerance. Insulin secretion assays showed that manipulation of Ca~v~β~3~ affected secretion only at elevated glucose concentrations ([Figures 4](#fig4){ref-type="fig"}L and [S2](#mmc1){ref-type="supplementary-material"}). This means that targeting Ca~v~β~3~ is not associated with risk for hypoglycemia, one of the main issues associated with the strategy of augmenting insulin secretion in patients with T2DM. Our data demonstrating that overexpression of Ca~v~β~3~ decreased GIIS also in human islets ([Figure 7](#fig7){ref-type="fig"}) support the notion that Ca~v~β~3~ may indeed represent a promising clinical target in the treatment of diabetes. To develop treatment strategies for diabetes targeting Ca~v~β~3~, two approaches can theoretically be considered. One is to decrease the level of Ca~v~β~3~ in pancreatic islets by ASO or small interfering RNA (siRNA) treatment, alternatively to transplant islets in which the endogenous expression levels of Ca~v~β~3~ have been suppressed. The other is to block Ca~v~β~3~ function. Although we did not pinpoint the exact mechanism of Ca~v~β~3~ action in the diabetes islets, regulation of inositol trisphosphate generation or interaction with binding partners, such as α1 subunit, might be involved. Here, we particularly proved the *in vivo* application using Ca~v~β~3~^−/−^ islets transplanted into HFD-fed mice. This may in the future pave the way for a gene therapeutic approach, where the expression of β cell Ca~v~β~3~ is suppressed prior to islets being transplanted. Obviously, aspects such as efficacy, specific delivery, and side effects require further considerations before we can proceed with such strategies. In whole-body Ca~v~β~3~-knockdown mice, we did not observe any phenotypic defects. However, there are some reports of abnormal behavioral activities in Ca~v~β~3~^−/−^ mice, such as reduced anxiety, increased aggression, increased nighttime activity, and impaired working memory, although some forms of hippocampus-dependent learning are enhanced ([@bib23], [@bib19]).

An important question is how Ca~v~β~3~ levels mechanistically are upregulated in diabetic mouse islets. A recent study showed that Ca~v~β~3~ protein is upregulated in diabetic rat hearts subsequent to streptozotocin treatment ([@bib13]), suggesting that diabetes may be associated with altered Ca~v~β~3~ protein levels in various cell types in multiple organs. Here, we found that pro-inflammatory cytokines, such as TNF-α or IL-1β, increased Ca~v~β~3~ levels in the pancreatic islets ([Figure S1](#mmc1){ref-type="supplementary-material"}). This is in line with a previous study demonstrating that Ca~v~β~3~ expression is significantly increased in dendritic cells following treatment with TNF-α and IL-1β for 3 days ([@bib4]). These findings imply that regulation of Ca~v~β~3~ by proinflammatory cytokines can be a universal mechanism regulating Ca^2+^ signaling in cells. Recent studies have suggested that islet inflammation is associated with diabetes progression, and pro-inflammatory cytokines may therefore be critically involved in islet dysfunction ([@bib8], [@bib12]). The detailed relationship between islet inflammation and the roles of Ca~v~β~3~ should be the focus of future studies and thereby give us valuable information how targeting Ca~v~β~3~ may restore diabetes.

In conclusion, we have shown that Ca~v~β~3~ is associated with a significant Ca^2+^ signaling dysfunction in diabetic mouse islets and that targeting of this subunit might have beneficial effects not only on Ca^2+^ handling but also on insulin release, thereby resulting in improved glucose homeostasis. With similar results obtained applying human islets, we propose that Ca~v~β~3~ may serve as a druggable target in diabetes.

Experimental Procedures {#sec4}
=======================

Experimental Animal Care and Preparation of Islets and Cells {#sec4.1}
------------------------------------------------------------

All experimental procedures were approved by the Pohang University of Science and Technology Institutional Animal Care and Use Committee (POSTECH-2015-0055-R1, POSTECH IACUC, Korea). C57BL/6J, B6.Cg-Lep^ob^/J male mice (Jackson Laboratory, Bar Harbor, ME, USA) were used. Ca~v~β~3~^−/−^ mice were generated and backcrossed over 18 generations as described previously ([@bib25]). Ca~v~β~3~ heterozygous (Cavβ~3~^+/−^) mice were backcrossed into C57BL/6J. Wild-type (Ca~v~β~3~^+/+^) and Ca~v~β~3~^−/−^ mice used for analyses were obtained by breeding Cavβ~3~^+/−^ mice. The animals were maintained with a 12-hr light/dark cycle with free access to water. Mice were sacrificed by cervical dislocation under anesthesia with CO~2~. Four-week-old mice were fed a 60% HFD (D12492, Research Diets, New Brunswick, NJ, USA) for 8 weeks, and body weight and food intake were monitored. Islets of Langerhans were isolated by collagenase digestion (1 mg/mL collagenase P; Roche Diagnostics, Indianapolis, IN) and subsequently handpicked under a stereomicroscope. Islets were cultured in RPMI 1640 medium (Gibco, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin at 37°C in a humidified atmosphere of 5% CO~2~ in air for one day before the experiment. Single-islet cells were obtained by shaking islets in Ca^2+^-free medium with Accutase (Gibco) and seeded on poly-[l]{.smallcaps}-lysine-coated glasses and cultured overnight in RPMI 1640 culture medium. For treatment with proinflammatory cytokines, islets were pooled and incubated at 20 ng/mL TNF-α (R&D Systems, Minneapolis, MN) or 20 ng/mL IL-1β (R&D Systems) in RPMI 1640 medium (Gibco) supplemented with 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37°C in a humidified atmosphere of 5% CO~2~ for 24 hr.

\[Ca^2+^\]~i~ Measurements {#sec4.2}
--------------------------

\[Ca^2+^\]~i~ was measured using the Fura2-AM method. Islets or islet cells were incubated with Fura2-AM (2 μmol/L; Invitrogen, Carlsbad, CA) in HEPES buffer (125 mM NaCl, 5.9 mM KCl, 2.56 mM CaCl~2~, 1.2 mM MgCl~2~, 25 mM HEPES, 3 mM glucose, and 0.1% BSA \[pH 7.4\]) for 30 min at 37°C under 5% CO~2~. After loading, glass coverslips containing islets and cells were mounted into an open perifusion chamber and maintained at 37°C, and \[Ca^2+^\]~i~ was measured as the 340/380 nm fluorescence ratio. Islets were stimulated with 11 mM glucose, 25 mM KCl, or 200 μM Cch (Sigma-Aldrich). The light source was equipped with a xenon arc lamp and an integrated shutter (Lambda DG-4; Sutter Instrument Company, Novato, CA) and coupled to the microscope (IX 71; Olympus, Tokyo, Japan) via a liquid light guide. Sixteen-bit gray-scale images with a binning of 1 × 1 were captured every second (exposure time ∼100 ms) with a cooled electron multiplying charge-coupled device (EM-CCD) camera (ImagEM X2; Hamamatsu Photonics, Hamamatsu, Japan). The camera and shutter were controlled by MetaFluor software (MDS Analytical Technologies, Sunnyvale, CA). Data were analyzed with the same software. Cells with bright \[Ca^2+^\]~i~ signal defined the regions of interest (ROIs). ROI signals were calculated by subtracting background noise signal. \[Ca^2+^\]~i~ oscillations were analyzed using power spectral analysis in MATLAB (MathWorks, Lowell, MA) with a code adapted for analysis of the oscillations in pancreatic islets ([@bib38]) with modification. Oscillation amplitude values were calculated as the square root of the total power of periods from 6 to 600 s. The fast Fourier transform power spectrum was used to determine the dominating oscillation period from respective power spectra.

SDS-PAGE and Immunoblot Analysis {#sec4.3}
--------------------------------

Islets were lysed in Laemmli sample buffer and heated at 95°C for 5 min. Proteins were separated in SDS-PAGE gels (6%--16% gradient) and transferred to nitrocellulose membranes (Whatman, Maidstone, UK). Blots were blocked for 30 min with 5% skim milk, incubated with Ca~v~β~3~ antibody (1:2,000; C1978; Sigma-Aldrich), BIP (1:1,000; 3177; Cell Signaling Technology, Danvers, MA), ATF-6α (1:100; sc-166659; Santa Cruz Biotechnology, Santa Cruz, CA), or ARE1α (1:1,000; 3294; Cell Signaling Technology) at 4°C overnight and washed 3 times with washing buffer (50 mM Tris aminomethane, 150 mM NaCl, and 0.05% Tween). The membranes were incubated with secondary antibody (rabbit) at room temperature for 1 hr and washed 3 times with washing buffer. Immunoreactive bands were visualized with the ECL Plus immunoblotting detection system (Thermo Scientific, Waltham, MA).

Recombinant Adenovirus and Antisense Oligonucleotides {#sec4.4}
-----------------------------------------------------

Adenovirus-overexpressing Ca~v~β~3~ construct was generated through homologous recombination between linearized pAd-Track-CMV vector carrying either Flag2-wild-type (WT) or Flag2-Ca~v~β~3~ and the adenoviral backbone vector pAd-Easy. Ad-GFP was used as a control for all experiments. Viruses were purified with an Adeno-X Maxi purification kit (Clontech Laboratories, Palo Alto, CA, USA) and titrated according to the manufacturer's instructions. Antisense oligonucleotides, a series of chimeric 20-mer phosphorothioate oligonucleotides containing 2′-O-methoxyethyl groups at positions 1--5 and 16--20 targeted to mouse Ca~v~β~3~, were synthesized and purified (Integrated DNA Technologies, Coralville, IA, USA). Adenovirus and antisense oligonucleotides were added directly to pancreatic islet in the culture medium, 4 hr and overnight, respectively.

Glucose and Insulin Tolerance Tests {#sec4.5}
-----------------------------------

For glucose tolerance tests, mice were fasted overnight and 1 g/kg of [d]{.smallcaps}-glucose (Sigma-Aldrich) was injected intraperitoneally. For insulin tolerance tests, mice were fasted for 4 hr and 0.2 U/kg of insulin (Eli Lilly, Indianapolis, Indiana, USA) was injected intraperitoneally. Blood samples were collected at 0, 15, 30, 60, and 120 min after injection by tail bleeding. Blood glucose levels were determined using a glucometer (Accu-Check Active, Roche Diagnostics).

Insulin Release {#sec4.6}
---------------

Ten islets isolated from corresponding mice were pooled and incubated at 3 mM or 11 mM glucose in HEPES buffer for 30 min at 37°C. The conditioned buffer was collected, and insulin concentration was measured with the Rat/Mouse Insulin ELISA kit (ALPCO Diagnostics, Salem, NH), according to manufacturer's instruction. GSIS data are normalized by the number of islets. For experiments with human islets, groups of 10 human islets infected with Ad-GFP or Ad-Ca~v~β~3~ were preincubated with 3 mM glucose in Krebs buffer at 37°C for 1 hr. Subsequently, preincubated islets were treated with 3 mM glucose and then 11 mM glucose in Krebs buffer at 37°C for 1 hr. Samples were collected for insulin secretion assay. Insulin concentrations in the collected samples were determined by using AlphaLISA assay. Krebs buffer consisted of (in mM) 119 NaCl, 20 HEPES, 4.6 KCl, 2 CaCl~2~, 1 MgSO~4~, 0.15 Na~2~HPO~4~, 0.4 KH~2~PO~4~, 5 NaHCO~3~, and 0.1% BSA (pH 7.4). Human pancreata were obtained within the Nordic Network for Islet Transplantation from deceased donors. This study includes pancreatic islets from 3 donors. The experiments were approved by the Regional Ethical Review Boards in Uppsala and in Stockholm.

Islet Transplantation {#sec4.7}
---------------------

Mice were fasted overnight and then injected with 150 mg/kg of streptozotocin (Sigma-Aldrich) via intraperitoneal injection. When the glucose level was \>300 mg/dL, 0.2 U/kg/day of insulin (Eli Lilly) was injected to maintain glycemia. Islets were isolated from donor mice, and ∼100 islets were transplanted into the anterior chamber of the eye of the recipient mouse ([@bib36]).

Electrophysiological Recordings {#sec4.8}
-------------------------------

Adenovirus-infected single islet cells were subjected to conventional whole-cell patch-clamp analysis with an EPC-10 patch-clamp amplifier (HEKA Elektronik, Lambrecht/Pfalz, Germany). The cells were bathed in the external solution (138 mM NaCl, 10 mM TEACl, 10 mM CaCl~2~, 5.6 mM KCl, 1.2 mM MgCl~2~, 5 mM HEPES, and 3 mM glucose \[pH 7.4\]). Borosilicate glass electrodes (1.2 mm outside diameter; Warner Instrument, Hamden, CT) were pulled with a vertical pipette puller (PC-10; Narishige, Tokyo, Japan), and the recording pipette had tip resistances ranging between 2 and 3 MΩ when filled with pipette solution (150 mM N-methyl-D-glucamine, 2 mM CaCl2, 10 mM EGTA, 1 mM MgCl~2~, 5 mM HEPES, and 20 mM ATP \[pH 7.2\]). All recordings were performed at room temperature. The amplitude of whole-cell Ca^2+^ currents was normalized to cell capacitance. Acquisition and analysis of data were done using Patchmaster (HEKA Elektronik).

Statistics {#sec4.9}
----------

All results are presented as means ± SEM. An unpaired Student's t test was used for pairwise comparisons. Statistical significance of results from glucose and insulin tolerance tests were assessed by two-way repeated- measures ANOVA followed by multiple comparison with Bonferroni's correction. A p value \< 0.05 was considered statistically significant.
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